Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytokine Levels in Persistent DME Treated With Triamcinolone Acetonide
NCT02221453Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triamcinolone acetonide in diabetic macular edema (DME), sponsored by Unity Health Toronto. Primary endpoint: Change in cytokine levels. Started Sep 2015; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02221453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221453.